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Abstract: Since their discovery in 1985, fullerenes have been investigated extensively due to 
their unique physical and chemical properties. In recent years, studies on functionalized fullerenes 
for various applications in the field of biomedical sciences have seen a significant increase. 
The ultimate goal is towards employing these functionalized fullerenes in the diagnosis and 
therapy of human diseases. Functionalized fullerenes are one of the many different classes of 
compounds that are currently being investigated in the rapidly emerging field of nanomedicine. 
In this review, the focus is on the three categories of drug delivery, reactive oxygen species 
quenching, and targeted imaging for which functionalized fullerenes have been studied in 
depth. In addition, an exhaustive list of the different classes of functionalized fullerenes along 
with their applications is provided. We will also discuss and summarize the unique approaches, 
mechanisms, advantages, and the aspect of toxicity behind utilizing functionalized fullerenes 
for biomedical applications.
Keywords: fullerenes, functionalized fullerenes, nanomedicine, drug delivery, buckysomes, 
radiation protection
Introduction
Next year will mark 25 years since the third allotrope of carbon, namely fullerenes, were 
discovered in 1985.1 During these 25 years, fullerenes have captured the imagination of 
scientists due to their unique physical and chemical properties. Buckminsterfullerene 
(C60) is a truncated icosahedron containing 60 carbon atoms with C5–C5 single bonds 
forming pentagons and C5–C6 double bonds forming hexagons.1 The diameter of a C60 
fullerene molecule is 0.7 nm, hence it is an important member of the nanomaterials 
family. However, C60 has poor solubility in aqueous solvents coupled with a tendency 
to form aggregates in aqueous solutions, which makes it an unattractive candidate in 
biological applications.2,3 This problem has been solved to a great extent by various 
chemical and supramolecular approaches to functionalize fullerenes.4–6 Some of the 
functionalized fullerenes have excellent solubility in polar solvents and easily overcome 
the hurdles posed by C60.
Nanomedicine, a combinatorial approach using nanotechnology and medicine, has 
become an increasingly important field of research for diagnostics and theranostics.7–9 
The field of nanomedicine involves the design and development of novel nanomaterials 
(Figure 1) such as multifunctional liposomal nanoparticles,10–12 functionalized 
fullerenes,13–15 functionalized nanotubes,16 iron oxide nanoparticles,17 polymeric 
micelles,18 dendrimers,19 nanoshells,20 and polymeric microspheres.21 Once engineered, International Journal of Nanomedicine 2009:4 262
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these novel nanomaterials are then investigated to diagnose 
and treat major ailments such as cancer,22 heart,23 lung, and 
blood diseases.24 Drug delivery,25 reactive oxygen species 
(ROS) quenching,26–28 and targeted imaging29 have been some 
of the major areas of focus in nanomedicine.7
In this review, we discuss the role of functionalized 
fullerenes as a novel nanomaterial in biomedical applications 
with regard to the above mentioned three major areas of 
focus. We summarize the approaches used to functionalize 
fullerenes, their mechanism of action, comparative advantages 
of employing functionalized fullerenes and briefly discuss 
the aspect of toxicity in biological systems. We restrict the 
scope of this review to articles featuring functionalized 
fullerenes based on C60 platforms. Even though modification 
of fullerenes based on C70-based platforms have been 
well investigated, there is a lack of progress in the in vivo 
biomedical applications of C70-based platforms in the areas 
of drug delivery, ROS quenching, and targeted imaging. 
Since the number of novel functionalized fullerenes is 
rapidly expanding, we have created an exhaustive list 
(Table 1) of functionalized fullerenes along with their potential 
biomedical applications using previous review articles on this 
topic.30–37 In addition, this review will emphasize the clinical 
applications of a certain group of fullerenes functionalized 
with amphiphilic and dendritic groups by Hirsch and 
colleagues.13–15 Our research group has been investigating 
the use of amphiphilic fullerenes38,39 and dendritic fullerenes 
for drug delivery and ROS quenching, respectively. We have 
successfully demonstrated that amphiphilic fullerenes 
are capable of forming spherical vesicles in the order of 
100–150 nm termed “buckysomes.”38 These buckysomes can 
serve as drug delivery vectors to carry hydrophobic drugs 
such as paclitaxel to destroy cancer cells.39
List of functionalized fullerenes
Table 1 serves as a reference guide and provides a list 
of functionalized fullerenes that have been investigated 
for potential applications in biomedicine. The type of 
functionalized fullerene along with its potential use and the 
reference article are shown in this table.
The scope of this review is limited to the biological 
applications of functionalized fullerenes and not the synthesis 
aspect of modifying fullerenes. However, it is important 
to emphasize that the potential biological benefits can be 
realized only through novel modifications to fullerenes. 
On this note, credit must be given to all the fullerene chemists 
who have designed fullerenes to make them water soluble 
and thereby increase its ease of use in a biological system. 
Nanoshells Nanomedicine
Types of nanoparticles
Biomedical applications
of functionalized fullerenes
Multi-functional
liposomes
Functionalized
nanotubes
Drug-delivery
Radiation
protection
MRI
contrast agents
Gene therapy
Photodynamic
therapy
Silicon
nanoparticles
Functionalized
fullerenes
Quantum dots
Iron-oxide
nanoparticles
Polymeric
micelles
Figure 1 Schematic represents functionalized fullerenes as an important member of the rapidly emerging and expanding diverse nanomedicine family.
Abbreviation: MrI, magnetic resonance imaging.International Journal of Nanomedicine 2009:4 263
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In particular, Prof. Andreas Hirsch’s group at University 
Erlangen-Nuremberg, Germany, Prof. Maurizio Prato’s 
group at University of Trieste, Italy, and Prof. Lon Wilson’s 
group at Rice University, Texas, USA are pioneers in the 
design and synthesis of water soluble fullerenes.
Hirsch and colleagues have investigated the synthesis 
of supramolecular organization of dendritic amphiphiles 
that contain fullerenes or calixarenes as core units.13–15 
The “amphifullerene” compounds, which are based on a 
C60 core, contain both hydrophobic (water-insoluble) and 
Table 1 List of functionalized fullerenes and their potential applications in biomedicine
Type of functionalized fullerene  
(Keywords)
Potential application  References 
Amphiphilic fullerene 
(AF-1, buckysomes, PeB)
Drug delivery Brettreich14  
Burghardt15  
Partha38  
Partha39
Dendrofullerene (DF-1) radioprotection Brettreich13  
Daroczi40
Fullerene–paclitaxel Cancer therapy Zakharian41
Fullerene polyamine (tetraamino 
fullerene)
Gene delivery, transfection Nakamura42  
Isobe43  
Isobe44  
Isobe45
Amino-fullerene adducts Nonviral gene delivery Sitharaman46
Fullerene-based amino acids 
and peptides
Peptide delivery Bianco47  
Yang48  
Yang49
Cystine C60, Beta-alanine C60 H2O2-induced apoptosis 
Protection
Hu50  
Hu51
Fullerene lipidosome Anti-viral activity Ji52
Fullerene doped liposomes (LMIC) Photodynamic cancer therapy Ikeda53  
Doi54
Fullerene-liposomes Antioxidant Lens55
Fullerene vesicle Oxidative stress reduction Maeda56
Gadofullerenes MrI contrast agents Bolskar57  
Tóth58  
Sitharaman59  
Bolskar60  
Fatouros61
Hydrophilic or cationic fullerenes  
 
Human serum albumin-fullerene 
Fullerene hexaadducts  
PEG-modified fullerene
Photodynamic cancer therapy Mroz62  
Mroz63  
Qu64  
rancan65 
Tabata66
Fullerenol  
 
 
 
 
Carboxy fullerene  
Polymer encapsulated fullerene
Free radical scavenger Dugan67  
Tsai68  
Lai69  
Injac70  
Injac71  
Dugan72 
Murthy73
Hydrated fullerene Treating alcohol-induced 
encephalopathy
Tykhomyrov74
Fullerene based nanocationite Myocardial hypoxia Amirshahi75
C3-F-tris-MDC Oxidative stress reduction Bisaglia76
Carboxy fullerene  
Ascorbic acid-fullerene
Antioxidant Lin77  
Monti78  
Santos79
Bisphosphonate fullerene Bone therapeutic agent Gonzalez80
Abbreviations:   AF-1, amphiphilic fullerene-1; PeB, paclitaxel-embedded buckysomes; DF-1 dendrofullerene-1; LMIC, Lipid membrane incorporated fullerenes; C3-F-tris-MDC, 
C3-fullero-tris-methanodicarboxylic acid.International Journal of Nanomedicine 2009:4 264
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hydrophilic (water-soluble) moieties and self-assemble to 
form supramolecular structures referred to as “buckysomes.”38 
These buckysomes are the first reported instance of a water-
soluble fullerene that is capable of forming a vesicle through 
instantaneous self-assembly. Amphiphilic fullerene-1 (AF-1) 
is one such novel functionalized fullerene which can self-
assemble into either a hydrophilic vesicle with a hollow 
interior38 or a solid spherical nanostructure with a dense 
hydrophobic interior.39 The fullerene monomer AF-1, consists 
of a “buckyball” cage to which a Newkome-like dendrimer 
unit and ten hydrophobic C12 chains positioned octahedrally 
to the dendrimer are attached (Figure 2). The functional group 
at the top of the molecule is a dendritic moiety containing 
18 carboxylic acid groups. At the other five positions are 
pairs of C12 esters (dodecyl malonates). A recent collaborative 
effort between our group and Prof. Hirsch’s revealed that 
by increasing the temperature during the buckysome self-
assembly process, AF-1 forms a novel vesicular structure 
with the ability to encapsulate hydrophobic molecules.39 
These results were highly encouraging towards investigating 
the use of buckysomes as novel “nanovectors,” which deliver 
drugs to specific disease sites in the human body.
Buckminsterfullerenes are characterized as a “radical 
sponge” for their ability to add multiple radicals per 
each fullerene molecule.26 However, this radical scavenging 
feature can be exploited in a biological setting only when 
the molecule’s water solubility is enhanced. In 1994, 
Hirsch and Lamparth first reported the synthesis of water-
soluble malonic acid derivatives of C60 with a defined three-
dimensional structure. In a landmark research study, Dugan 
and colleagues72 used this Hirsch method to synthesize two 
specific regioisomers of carboxyfullerenes and demonstrated 
that they are effective radical scavengers and act as neuropro-
tective antioxidants in vitro and in vivo. EPR data from their 
study confirmed that these carboxyfullerenes retained the free 
radical scavenging potency of the parent fullerene molecule. 
Also, the neuroprotective efficacy of the carboxyfullerenes 
was enhanced due to their ability to react with superoxide 
radical in addition to hydroxyl radical. They further noted 
that the ability of these carboxyfullerenes to eliminate the 
superoxide radical before its conversion to the hydroxyl 
radical is a critical feature of their biologically relevant 
antioxidant properties. These malonic acid adducts of C60 are 
highly water soluble, have a well defined structure and exhibit 
stability. In 1998, the Hirsch group designed highly soluble 
monoadducts instead of the earlier reported trisadducts 
for neuroprotective applications.13 A dendrimer containing 
18 carboxylic acid groups was added as an addend to C60 
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Figure 2   A) The chemical structure of the amphiphilic fullerene (AF-1) monomer; B) Space-filling model of AF-1, depicting its length and width.International Journal of Nanomedicine 2009:4 265
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to give rise to a dendro[60]fullerene also known as DF-1. 
This novel functionalized fullerenes has shown remarkable 
antioxidant properties against the dangerous effects of 
ionizing radiation.40
Wilson and colleagues have been leaders in the pursuit 
of using gadolinium (Gd)-containing metallofullerenes 
termed “gadofullerenes” as new generation magnetic 
resonance imaging (MRI) contrast agents.57–60 For the first 
time, they demonstrated the use of a water-soluble Gd@
C60[C(COOH)2]10 derivative as a MRI contrast agent with 
a favorable biodistribution similar to existing clinically 
employed MRI contrast agents.57 The use of carboxyl 
functional groups to water solubilize the Gd-metallofullerenes 
had positive outcomes on excess reticuloendothelial 
system (RES) uptake, which was an issue of concern with 
polyhydroxylated fullerene derivates. To avoid the release 
of the metal ion in vivo during the metabolic processes, 
the technique of trapping the Gd3+ ion within a fullerene 
cage for each gadofullerene prevented the dissociation of 
the metal ion in vivo.59 Tóth and colleagues concluded that 
derivatized Gd@C60 nanomaterials in the order of 1.0 nm 
diameter offered paradigms in the nanoscale range for 
designing high performance MRI contrast agent probes 
which can be up to 20 times more efficient than current 
clinical contrast agents.58
During the past two decades, Prato’s group has played 
a leading role in the fields of synthesizing functionalized 
fullerenes, purification, and applications.33,47,80–84 They used 
software to model the fullerenes and proceeded to synthesize 
water-soluble fullerene derivatives. These were targeted to fit 
inside the hydrophobic cavity of human immunodeficiency 
virus (HIV) proteases thereby inhibiting the access of 
substrates to the catalytic site of the enzyme.81 The presence 
of two ammonium groups located on the spheroid surface of 
the fullerene moiety was considered to be critical elements 
for the anti-HIV activity. Recently, the synthesis of regioiso-
meric bis-fulleropyrrolidines bearing two ammonium groups 
was reported.82 The activities of two trans isomers against 
HIV-1 and HIV-2 were evaluated. The antiviral properties 
were attributed to the relative positions of the substituent 
on a C60 cage. In a review article published five years ago, 
Prato and colleagues discuss clearly the advances of fuller-
ene chemistry in the field of medicinal chemistry.84 They 
explain the synthesis of the biggest unnatural amino acid 
3,4-fulleroproline (Fpr) and the ability of Fpr derivatives 
to interact with various hydrolytic enzymes and selectively 
discriminate between rationally designed peptides. The 
review provides valuable information on the capabilities of 
fullerene-based peptides to activate enzymes involved in the 
oxidative deamination of biogenic amines.
Fullerenes have also been functionalized in a variety 
of other methods to make them suitable for biomedical 
applications. “Fullerenols” are polyhydroxylated fullerenes 
(C60(OH)n; n = 12–26) and are considered excellent anti-
oxidants due to their free radical scavenging ability.67–71 
As described earlier, fullerene-containing amino acids have 
been found to substantially modulate enzymatic activity and 
provide further insight into the structure-function relationship 
of proteins and enzymes.47–51 Another interesting method 
involves incorporating fullerenes either into the bi-layers 
of lipsomes termed lipid membrane incorporate fullerenes 
(LMIC)53,54 or encapsulating inside the liposomes.55,56 Other 
novel methods include complexing human serum albumin 
with functionalized fullerenes,63 poly-ethylene glycol (PEG)-
modified fullerenes,66 encapsulation of fullerenes in sugar-
based polymer,73 adsorption of ascorbic acid on fullerenes,79 
and a fullerene-paclitaxel chemotherapeutic.41 In summary, 
there is a large variety of methods to functionalize fullerenes 
to make them suitable in a biological setting. The method 
clearly is driven and governed by the potential application 
and toxicity profiles.
Biomedical applications 
of functionalized fullerenes
As shown in Table 1, functionalized fullerenes have a versatile 
and rapidly expanding list of biomedical applications. 
We will discuss the three major areas of drug delivery, ROS 
quenching, and role of MRI contrast agents in detail. We will 
also provide brief information on other potential applications 
of functionalized fullerenes in the fourth section.
Functionalized fullerenes  
as drug-delivery nanoparticles
Paclitaxel-embedded buckysomes (PEBs) are spherical 
nanostructures in the order of 100–200 nm composed of 
the amphiphilic fullerene, AF-1 embedding the anti-cancer 
drug paclitaxel inside its hydrophobic pockets.39 Similar to 
Abraxane®, the US Food and Drug Administration (FDA)-
approved drug for treating diseases such as metastatic 
breast cancer, our water-soluble fullerene derivatives enable 
the uptake of paclitaxel without the need for nonaqueous 
solvents, which can cause patient discomfort and other 
unwanted side effects. However, our preliminary studies 
indicate that PEBs might be capable of delivering even higher 
amounts of paclitaxel than those delivered via Abraxane®. 
By delivering an increased amount of paclitaxel, we can International Journal of Nanomedicine 2009:4 266
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hope to reduce infusion times and expect higher tumor 
uptake, resulting in a greater anticancer efficacy. Another 
attractive feature of our fullerene-based delivery vectors 
is that their nanoscale dimensions favor passive targeting, 
which enables them to accumulate at tumor sites by entering 
through leaky vasculature present in the endothelial cells 
of the tumor tissue. Additionally, the fullerene moiety can 
be easily functionalized to attach targeting agents, which 
facilitate active targeting. PEBs also provide an easy fea-
ture of adding targeting groups to their fullerene moieties. 
In PEBs, both liposomal and nanoparticle technologies are 
combined to create nanostructures that function as novel 
drug carriers. This approach is advantageous because it may 
improve circulation times in the blood, shields the anticancer 
drug against enzymatic degradation and reduces uptake by 
the reticuloendothelial system (RES). The size of the PEBs 
is designed to be less than 200 nm to avoid RES uptake. The 
presence of dendritic groups on the outside of the PEBs can 
also provide stealth function to reduce clearance.
We have previously described the effects of pH and various 
aqueous buffers (solvents) on the self-assembly of AF-1 into 
buckysomes.38 Interestingly, we found that buckysomes 
prepared at 70 °C (Figure 3) possess morphology conducive 
to the uptake of hydrophobic molecules.39 Notably, the 
dark contrast observed in the interior of these structures in 
cryo-electron microscopy images (Figure 3A) most likely 
corresponds to the presence of densely assembled aggregates 
of AF-1 monomers. The structures were confirmed using 
complementary freeze fracture (Figure 3B) and transmission 
electron microscopy (Figure 3C) techniques. To determine the 
efficacy of PEBs as an anticancer nanocarrier, we performed 
in vitro cell viability assays with MCF-7 human breast 
cancer cells using the trypan blue dye exclusion method 
(Figure 3, bottom left). Importantly, the empty buckysomes 
(B) did not hinder cell growth as compared to the buffer 
(A), demonstrating that the bucksyomes themselves were 
not cytotoxic. Interestingly, the results obtained with PEBs 
and Abraxane® was quite comparable. We believe that our 
V
i
a
b
l
e
 
c
e
l
l
 
n
u
m
b
e
r
 
(
1
0
5
)
0
A B C D
Sample
E
48 hr
72 hr
F G H
2
4
6
Figure 3 Functionalized fullerenes can function as drug-delivery agents for chemotherapy.   Top. A) Cryo-eM image showing the solid, dense spherical structures obtained upon 
self-assembly of AF-1 monomers at an elevated temperature of 70 °C; scale bar = 100 nm. B) Freeze-fracture micrograph (scale bar = 200 nm) and C) transmission electron 
micrograph (scale bar: = 500 nm) confirm the spherical morphology of the buckysomes in panel A and also indicate a similar size profile.   All three images were obtained from 
the same buckysome sample. Bottom. (Left) Trypan blue dye-based cell viability assay of MCF-7 cells. Samples were incubated for a period of 48 (gray bars) and 72 h (black 
bars) at 37 °C. Negative controls were 0.48 mM citrate buffer A) and empty buckysomes B).   The concentration of paclitaxel in the PeBs was 28.6 C), 143 E), and 714 ng/ml 
G).   The comparative positive control was Abraxane, with identical paclitaxel concentrations in columns D, F, and H, respectively. Bottom (right) Microscopic visualization of 
the morphology of live MCF-7 cells incubated with citrate buffer (1), empty buckysomes (2), PeBs (3), and Abraxane (4) for a 72-h time period.   The concentration of paclitaxel 
in images 3 and 4 is 714 ng/ml.   These images were collected from the same samples used in the assay shown in left.   The scale bars in all four images are 250 µm. Copyright © 
2008, American Chemical Society. reprinted with permission from Partha r, Mitchell Lr, Lyon  JL, Joshi PP, Conyers  JL. Buckysomes: fullerene-based nanocarriers for hydro-
phobic molecule delivery.   ACS Nano. 2008;2(9):1950–1958.International Journal of Nanomedicine 2009:4 267
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nanocarrier without a stabilizing agent such as albumin can 
deliver paclitaxel in higher quantities to the cancer cells by 
endocytosis. During the course of the MCF-7 cell viability 
assay we simultaneously monitored the cells’ morphological 
changes using optical microscopy. The images (Figure 3, 
bottom right) clearly correlated with the results obtained in 
the viability studies. These observations again confirmed 
that the empty buckysomes were not cytotoxic. The images 
in panels 1 and 2 differ remarkably from those observed 
upon delivery of 714 ng/ml of paclitaxel by both the PEBs 
(inset 3) and Abraxane® (inset 4) at 72 hours. In both 
of these cases, MCF-7 cells are sparser in appearance, 
indicating that the delivered paclitaxel hindered the cell 
division process. We observed similar results at 48 hours. 
These in vitro studies have demonstrated that PEBs’ efficacy 
toward MCF-7 human breast cancer cells is comparable to 
that of Abraxane®, and we are currently investigating PEBs 
in preclinical trials using murine models as a necessary step 
toward clinical testing and ultimate approval of the PEBs for 
human use. At the conclusion of these studies, we will be 
able to determine whether our fullerene-based nanoparticle 
carriers are an effective core technology for enhanced 
paclitaxel delivery in vivo.
The ability of fullerene to produce an ideal lipophilic 
slow-release system and provide three-dimensional scaf-
folding for covalent attachment of multiple drugs can be 
used to create single-dose “drug cocktails.” In the article by 
Zakharian and colleagues, a fullerene–paclitaxel conjugate 
was designed to slowly release the drug for aerosol liposome 
delivery of paclitaxel for lung cancer therapy.41 The aggregate 
size range for this conjugate was in the order of 120–145 nm 
and the size did not vary with concentration. This conjugate 
was designed to release paclitaxel via enzymatic hydrolysis 
with a half-life of release of 80 min in bovine plasma. 
A dilauroylphosphatidylcholine (DLPC)-based liposome 
formulation of the conjugate was reported to have a half 
maximal inhibitory concentration (IC50) value virtually 
identical to the IC50 for a paclitaxel–DLPC formulation in 
human epithelial lung carcinoma A549 cells. They concluded 
that with both clinically relevant kinetics of hydrolysis and 
significant cytotoxicity in tissue culture, the fullerene–
paclitaxel conjugate had potential for enhanced therapeutic 
efficacy of paclitaxel in vivo.
Aside from delivering drug molecules, functionalized 
fullerenes have also been examined as transfection vec-
tors to deliver exogenous DNA into cells and tested for 
their ability to mediate gene transfer.42–45 This technique 
has possible benefits in gene therapy. Although the first 
generation fullerene transfection vectors showed promise, 
they also exhibited high cytotoxicity.44 Sitharaman and 
colleagues successfully demonstrated that a new class of 
water-soluble C60 derivatives prepared using Hirsch–Bingel 
chemistry can uptake DNA, transport them across the cell 
and elicit gene expression.46 However, the study shows that 
only two positively charged C60 derivatives, an octa-amino 
derivatized C60 and a dodeca-amino derivatized C60 vector, 
showed efficient in vitro transfection. Aggregation behavior 
was presumed to cause increased cytotoxicity of certain 
functionalized fullerenes. Therefore, it was suggested that 
future studies should address this issue of aggregation in 
the presence of DNA before designing the derivative. They 
have also suggested the possibility to develop analogous 
gadofullerene vectors for a combinatorial approach of 
diagnosis and therapy.
reactive oxygen species (rOS) quenching 
by functionalized fullerenes
Ever since Krusic and colleagues documented the potential of 
fullerenes to scavenge ROS,26 there has been a great interest in 
using fullerenes as an antioxidant. However, it is important to 
remember that while functionalizing fullerenes to make them 
water soluble, the free radical scavenging properties must be 
maintained. In 1997, Dugan and colleagues published a path-
breaking article on “carboxyfullerenes as neuroprotective 
agents.”72 They suggested that C60 derivatives might constitute 
antioxidant compounds useful in biological systems. 
Carboxyfullerene were efficient against excitotoxic necrosis 
and provided protection against two forms of neuronal 
apoptosis. This led to the idea that oxidative stress is a critical 
downstream mediator in disparate necrotic and apoptotic 
neuronal deaths. The study also showed that amphiphilicity 
is a desirable feature in the functionalization, increasing 
intercalation into brain membranes and neuroprotective 
efficacy. The article demonstrated that C60 derivatives can 
indeed function as neuroprotective drugs in vivo.
In another study, Lin and colleagues presented in vitro 
data demonstrating that carboxyfullerenes possesses an 
antioxidative property and is capable of suppressing iron-
induced lipid peroxidation.77 Their in vivo study showed 
neuroprotection by carboxyfullerene against iron-induced 
degeneration of the nigrostriatal dopaminergic system. Also, 
they reported that the intranigral infusion of carboxyfullerene 
appeared to be nontoxic to the nigrostriatal dopaminergic 
system of rats. Other research studies that followed, con-
firmed the protective activity of carboxyfullerenes against 
oxidative stress and their potential as a free radical scavenger. International Journal of Nanomedicine 2009:4 268
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Monti and colleagues found that carboxyfullerene was able 
to protect quiescent human peripheral blood mononuclear 
cells from apoptosis by a mechanism partially involving the 
mitochondrial membrane potential integrity, known to be 
associated with early stages of apoptosis.78 They concluded 
that these results represented the first indication for a target 
activity of buckminsterfullerenes on cells of the immune 
system and their mitochondria.
Dicker and colleagues tested the hypothesis that the 
antioxidant properties of the dendrofullerene, DF-1, would 
help alleviate the toxicity from radiation exposure.40 They 
compared the effect of DF-1 with the FDA-approved drug 
amifostine in vivo in a zebrafish (Danio rerio) model. The 
article reported that radiation exposure of zebrafish embryos 
produced extensive edema in the developing fish, and this effect 
was reversed by DF-1 treatment. To obtain a more detailed 
view of DF-1-mediated radioprotection, they evaluated the 
effects of this drug on organ-specific, radiation-induced 
damage. They assessed the effects of DF-1 on a commonly 
observed phenotype that was apparent within one to two 
days following ionizing radiation exposure (10–40 Gy) of 
zebrafish. This phenotype described as ‘‘curly-up’’ or cup and 
was ascribed to defects in midline development of zebrafish 
embryos. The study concluded that throughout the dose 
range tested, DF-1 markedly reduced the incidence of cup. 
Depending on the ionizing radiation dose, it either reduced 
the severity or abolished the dorsal curvature altogether 
(Figure 4). It was significant to note that DF-1 did not cause 
any adverse effects on normal zebrafish morphology or 
viability in the concentration range tested (1–1,000 µmol/L). 
DF-1 (100 µmol/L) was reported to markedly attenuate 
overall and organ-specific radiation-induced toxicity when 
given within three hours before or up to 15 minutes after 
radiation exposure. However, DF-1 did not afford protec-
tion when given 30 minutes after ionizing radiation. The 
degree of radioprotection of DF-1 was comparable with 
amifostine (4 mmol/L). The study also showed that protection 
against radiation-associated toxicity using DF-1 in zebrafish 
embryos was associated with marked reduction of radiation-
induced ROS. In summary, the authors concluded that DF-1 
offered excellent antioxidant properties against radiation-
induced damage. This study has implications in developing 
drugs for the military in the event of radiation attacks.
Chen and colleagues28 reported that three different 
types of water-soluble fullerenes materials can intercept 
all of the major physiologically relevant ROS. They used a 
carboxyfullerene derivative [C60(C(COOH)2)2] and a fullerenol 
derivative [C60(OH)22], and C82-derived gadofullerene. The 
study demonstrated that these functionalized fullerenes can 
protect cells against hydrogen peroxide-induced oxidative 
damage, stabilize the mitochondrial membrane potential 
and reduce intracellular ROS production. The study reported 
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Figure 4 Functionalized fullerenes offers protection from radiation-induced cell damage. DF-1 protects against radiation-induced defects in midline development. 
radiation-induced morphologic changes in body axis were assessed at 3 dpf. representative pictures of ionizing radiation-induced dorsal curvature (cup phenotype) in 
zebrafish and attenuation of this effect by DF-1 (100 µmol/L) given three hours before ionizing radiation (24 hpf). Quantitative representation of the results after 20 or 40 Gy 
ionizing radiation as indicated. Copyright © 2006,   American   Association for Cancer research, Inc. reprinted with permission from Daroczi B, Kari G, McAleer MF,   wolf  JC, 
rodeck U, Dicker AP. In vivo radioprotection by the fullerene nanoparticle DF-1 as assessed in a zebrafish model. Clin Cancer Res. 2006;12(23):7086–7091.
Notes: *P = 0.0077, statistically significant differences between control and experimental groups.International Journal of Nanomedicine 2009:4 269
Biomedical applications of functionalized fullerenes Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
that size of the nanoparticles can affect antioxidant and ROS 
quenching potency. The explanation was that a suspension of 
larger nanoparticles would provide less reactive sites for the 
ROS, thereby reducing the efficiency of scavenging reactive 
species. In addition, size may influence the distribution 
of nanoparticles in cells and in tissues. In vitro studies 
using human lung adenocarcinoma cell line A549 and rat 
brain capillary endothelial cell line (rBCECs) indicated 
that these functionalized fullerenes reduces hydrogen 
peroxide-induced cytotoxicity, free radical formation, and 
mitochondrial damage (Figure 5). This result indicates that 
the gadofullerene derivative protected against oxidative 
injury to cellular mitochondria better than other two fullerene 
derivatives. Their study represented the first report that 
different types of fullerene derivatives can scavenge all 
physiologically relevant ROS. The article concluded that 
the role of oxidative stress and damage in the etiology and 
progression of many diseases suggests that these fullerene 
derivatives may be valuable in vivo cytoprotective and 
therapeutic agents.
role of functionalized fullerenes  
as MrI contrast agents
Endohedral metallofullerenes are another class of 
functionalized fullerenes that can encapsulate the metal atom 
inside the fullerene cage. The ability to design water-soluble 
derivatives of endohedral metallofullerenes has played a key 
role in utilizing these compounds for medicinal applications. 
Analogous to a liposome protecting its encapsulated drug, 
the fullerene cage in a metallofullerene protects the metal 
inside both against chemical or enzymatic activity within 
the body and the unwarranted release of the metal. In this 
context, Gadolinium-encapsulated fullerenes have been 
proposed as contrast agents to enhance MRI quality.56–61 
Another feature of the gadofullerenes as a contrast agent 
for MRI is ensuring the metal atom is held within the 
cage for applications that might require longer residency 
times. Tóth and colleagues were the first to report the 
nuclear magnetic relaxation profiles for two water-soluble 
functionalized fullerenes, namely Gd@C60(OH)x and 
Gd@C60[C(COOH)2]10.58 They concluded that the strong 
pH dependency of the proton relaxivities made these 
functionalized fullerenes great candidates for MRI contrast 
agents with a stimulus based on pH.
In a follow-up study, Sitharaman and colleagues showed 
that the anionic gadofullerene {Gd@C60[C(COOH)2]10} 
was an attractive candidate for ex vivo labeling and nonin-
vasive in vivo tracking of any mammalian cell via MRI.59 
The experiments on cellular internalization experiments 
indicated that complete labeling of the anionic gadofullerene 
was achieved for marrow stromal cells within 2–8 hours 
of incubation with further increase in uptake beyond the 
eight-hour time point. Also, the supernatant obtained from 
the pulse-chase experiments showed no detectable Gd 
content, whereas the cells showed similar Gd concentrations 
at all time points. Based on these findings, they indicated 
that the gadofullerene did not leach after labeling and that 
the labeling process is irreversible under these conditions. 
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Figure 5 Functionalized fullerenes can play a protective role against hydrogen peroxide induced mitochondrial damage. The protective effects of three fullerene derivatives 
Gd@C82(OH)22, C60(OH)22, and C60(C(COOH)2)2 against H2O2-induced mitochondrial damage in A549 cells, and rBCeC cells. The cells were treated with 100 µm fullerene 
derivatives before incubation with 50 µm H2O2. Aggregation of the dye, JC-1, seen as red fluorescence, indicates integrity of the mitochondrial membrane. Copyright © 2009, 
elsevier. reprinted with permission from Yin JJ, Lao F, Fu PP, et al.   The scavenging of reactive oxygen species and the potential for cell protection by functionalized fullerene 
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The results also indicated that cellular labeling with this 
fullerene derivative is intracellular and/or that the magnetic 
labels are intercalated deep within the cell membrane. In vitro 
cell viability and toxicity assays revealed no cell damage as 
a result of this labeling. T1-weighted MRI phantoms from 
the study clearly demonstrated that the signal intensity of 
Gd@C60[C(COOH)2]10 was about 300% greater than that 
of clinically used Gd-DTPA (Magnevist™) at 0.04 mM 
concentration of gadolinium. They also concluded that 
at the same concentration of Gd, commercially available 
Gd-DTPA yielded little enhancement compared with plain 
distilled water. They also stated that the high relaxivity of 
the gadofullerenes substantially reduced the T1 of labeled 
cells, even at modest concentrations of gadolinium, and 
this difference in T1 between labeled and unlabeled cells 
might allow for their direct discrimination with clinical MRI 
imagers at 1.5T. According to the study, this is significant 
for detection of stem cells, by MRI at resolutions that can 
potentially be achieved in vivo in animals and humans. 
Fatouros and colleagues conducted studies on water-soluble 
Gd3N endohedral metallofullerenes functionalized with 
poly(ethylene glycol) and multihydroxyl groups [Gd3N@
C80[DiPEG5000(OH)x] and demonstrated that they offer 
great potential for serving as MRI contrast agents due 
to their T1–T2 relaxivity characteristics – approximately 
40 times greater than conventional gadolinium-containing 
MRI contrast agents.61
Other potential applications
Fullerenes have the unique ability to quench ROS and 
generate ROS under specific conditions. Fullerenes have an 
extended π-conjugation which allows them to absorb visible 
light and have a long-lived triplet yield. This property results 
in the generation of ROS upon illumination with light. This 
special of ROS generation has resulted in the possible role 
of fullerenes in photodynamic therapy (PDT). PDT involves 
the combination of nontoxic photosensitizers and harmless 
visible light to generate ROS and kill cells. Depending on the 
functionalized fullerene, they can effectively photoinactivate 
either or both pathogenic microbial cells and malignant 
cancer cells. Mroz and colleagues described this mechanism 
to involve superoxide anion as well as singlet oxygen, 
and under the right conditions fullerenes to have possible 
benefits over clinically applied photosensitizers for mediating 
photodynamic therapy of certain diseases.63
The formation of intracellular ROS was shown by 
Mroz and colleagues in a study that demonstrated that 
functionalized fullerenes with pyrrolidinium groups 
mediated photodynamic killing of cancer cells.62 They 
used a reactive intracellular probe to determine if ROS 
(particularly hydrogen peroxide) were produced in cells that 
had been incubated with fullerenes and illuminated. Figure 6 
shows the fluorescence micrographs of illuminated murine 
cancer cells that had been incubated with either the probe 
without fullerene (panel A) or the functionalized fullerene 
for 24 hours followed by the probe (panel B). There was 
only trace green fluorescence visible in cells with probe 
alone, while the cells that had both fullerene and probe 
demonstrated a large increase in fluorescence that was evenly 
distributed throughout the cells. The result was consistent 
with a diffusible species such as hydrogen peroxide having 
been produced during illumination. The study concluded that 
monocationic fullerene is a highly effective photo sensitizer 
for killing cancer cells by rapid induction of apoptosis after 
illumination and the mechanism involved type I and type II 
processes. Various other functionalized fullerene derivatives, 
have been previously investigated to carry out PDT-induced 
killing of mammalian cells in tissue culture,65 and another 
reported on regressions after PDT in a mouse tumor model.66 
Fullerene incorporated liposomes have also been studied 
for photodynamic activity.53–55
Functionalized fullerenes with peptides and amino acids 
have been found to substantially activate enzymes involved 
in the oxidative deamination of biogenic amines.47 The 
presence of the fullerene-substituted amino acid in a peptide 
was reported to have a significant effect on the secondary 
structures and self-assembly properties of peptides as 
compared to the native peptide.48 Gonzalez and colleagues 
reported for the first time that a fullerene-based material 
can be successfully targeted to a selected tissue.79 A tissue-
vectored bisphosphonate fullerene designed to target bone 
tissue was synthesized and evaluated in vitro. The idea 
was that an amide bisphosphonate addend, in conjunction 
with multiple hydroxyl groups, confered a strong affinity 
for the calcium phosphate mineral hydroxyapatite of bone. 
Table 1 provides a list of references which have investigated 
functionalized fullerenes for many other potential biomedical 
applications.
Aspect of toxicity
The rapid growth of nanotechnology in the past two 
decades has generated intense discussions on the safety 
and toxicity aspect of nanomaterials upon accidental 
exposure to humans and the environment itself.85,86 The 
need to address this aspect has strengthened since a large 
number of these nanomaterials have potential for usage in International Journal of Nanomedicine 2009:4 271
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a biological system, a key component in the new field of 
nanomedicine.7 Oberdörster conducted the first study that 
showed uncoated fullerenes to cause oxidative stress in the 
brain and depletion of glutathione levels in juvenile large-
mouth bass species.87 The initial study was performed with 
tetrahydrofuran-solubilized nC60 and a later study used water 
solubilized nC60.88 Blickley and colleagues concluded that 
aqua-nC60 affects the oxidative stress response of adult and 
larval Fundulus heteroclitus.89 However, these studies were 
performed on nonfunctionalized fullerenes but nevertheless 
serve as a reminder on the importance of conducting toxicity 
assays on functionalized fullerenes which have potential for 
clinical use.
In another preclinical study on acute oral administration 
of fullerenes in mammals (Sprague-Dawley rats), fullerenes 
were administered once orally to a single group of male 
and female at a dose level of 2,000 mg/kg. No deaths were 
observed and the body weights in both sexes of 2,000 mg/kg 
group increased in a similar pattern to the control group. 
In this case, they concluded that fullerenes did not induce 
acute oral toxicity, nor in vitro genotoxicity.90 Another 
report indicated that carbon based nanomaterials with 
different geometric structures (nanotubes versus fullerenes) 
exhibit quite different cytotoxicity and bioactivity in vitro, 
although they may not be accurately reflected in the 
comparative toxicity in vivo.91 It is interesting to note 
that Colvin and colleagues hypothesized that sparingly 
soluble fullerenes will cause oxidative damage to cellular 
membranes even at relatively low concentrations, and that 
the resulting toxicity will diminish as the fullerene cage 
becomes more fully derivatized and water soluble.92 They 
subsequently reported that cytotoxic activity of THF/C60 
occurred through ROS-mediated cell membrane lipid 
peroxidation.93 This reiterates the importance of function-
alized fullerenes which have a high degree of solubility in 
water. For instance, our in vitro studies on supramolecular 
structures of AF-1 in the concentration range 10–200 µM 
did not reveal any toxicity.38 In an in vivo model, DF-1 
had no apparent adverse effects on normal zebrafish 
morphology or viability throughout the concentration range 
tested (1–1,000 µmol/L).40
In a review article, Nielsen and colleagues describe 
fullerenes as a “double-edged sword,” having beneficial 
effects at low concentrations, but at high concentrations 
they may be able to induce inflammation and if chronic, 
may promote development of cancer.94 They conclude that 
the current data suggests that direct DNA-damaging effects 
are low, but formation of ROS may cause inflammation and 
genetic damage. As a result, dose-dependency determines 
whether effects can be beneficial or harmful. Also, the need to 
tightly control ROS-dependent biological effects of different 
fullerene preparations can be a challenge in their potential 
A B
Figure 6 Functionalized fullerenes mediate photodynamic killing of cancer cells. Fluorescence micrographs of J774 cells that had been incubated with intracellular reactive 
oxygen species probe H2DCFDA, illuminated with 5 J/cm2 405-nm laser, and imaged after 5 min. A) H2DCFDA without fullerene; B) BF4 for 24 h + H2DCFDA. Scale bar is 
100 µm. Copyright © 2007, elsevier. reprinted with permission from Mroz P, Pawlak A, Satti M, et al. Functionalized fullerenes mediate photodynamic killing of cancer cells: 
Type I versus Type II photochemical mechanism. Free Radic Biol Med. 2007;43(5):711–719.International Journal of Nanomedicine 2009:4 272
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development for therapeutic use and clearly represents one 
of the principal goals.95 The aspect of toxicity of fullerene 
derivatives is clearly a contentious issues and there are 
several other studies and reviews which focus on both 
the absence and presence of toxicity on various fullerenes 
derivatives.96–107 The crucial aspect is not to interpret toxicity 
reports from various functionalized fullerenes, concentra-
tions, in vitro or in vivo models as a concluding answer but 
rather conduct specific toxicity assays based on the final 
application of interest.
Recently, Wick and colleagues107 demanded that future 
exposure and mechanistic studies should involve good 
characterization of the materials, careful preparation of 
each experimental design and special attention must be 
given to the solvents and media used within these studies. 
They concluded that many published data for which these 
prerequisites have not been fulfilled were not useful for an 
unbiased discussion of nanomaterial toxicity. A majority 
of the research papers that we have discussed in the review 
clearly clarify the need for further toxicity assays before 
claiming the clinical use of their functionalized fullerenes. 
On the positive side, some of these nanomaterials including 
certain functionalized fullerenes may provide great improve-
ments over existing medications and improve the quality of 
life for patients with severe diseases such as cancer or in cases 
of major disasters that can cause severe radiation exposure. 
All new technologies may bear a high amount of unknown 
factors along with lack of long term exposure risks but if 
the benefits offered are dramatic then they could overcome 
certain drawbacks.
Conclusions
In recent years, functionalized fullerenes have drastically 
changed the face of biological applications of C60. The credit 
goes to the creative and collaborative efforts of scientists 
who specialize in fullerene synthesis and nanomedicine. This 
merge is critical for both the chemistry behind designing the 
most effective modifications on the fullerenes and the biology 
behind successful diagnosis and therapeutic outcomes in 
disease. In this review we have provided an overview and 
an exhaustive list of the ever expanding research studies on 
using functionalized fullerenes to deliver drugs to diseased 
cells, act as an antioxidant to quench ROS, function as MRI 
contrast agents, and enhance the quality of noninvasive 
imaging of specific portions of the human body and for 
a multitude of other uses in biomedicine. At this current 
stage, these studies are limited to in vitro and in vivo pre-
clinical data and have not reached the stage of clinical trials. 
This is true not just for functionalized fullerenes but for a 
variety of other nanomaterials that are currently investigated 
for use in humans. One of the major reasons for the inability 
of these nanomaterials to translate into clinically approved 
drugs is the lack of consistent data on the toxicity profiles 
on animal models. However, with the rapid technological 
advancement in the field of nanomedicine, this scenario 
could change in the coming years so that the unique features 
of various functionalized fullerenes could be exploited in a 
clinical setting.
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